AU2013375208B2 - (22E)-2-methylene-22-dehydro-1a,24,25-trihydroxy-19-nor-vitamin D3 analogs - Google Patents

(22E)-2-methylene-22-dehydro-1a,24,25-trihydroxy-19-nor-vitamin D3 analogs Download PDF

Info

Publication number
AU2013375208B2
AU2013375208B2 AU2013375208A AU2013375208A AU2013375208B2 AU 2013375208 B2 AU2013375208 B2 AU 2013375208B2 AU 2013375208 A AU2013375208 A AU 2013375208A AU 2013375208 A AU2013375208 A AU 2013375208A AU 2013375208 B2 AU2013375208 B2 AU 2013375208B2
Authority
AU
Australia
Prior art keywords
patient
vitamin
compound
analogs
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013375208A
Other languages
English (en)
Other versions
AU2013375208A1 (en
Inventor
Rafal Barycki
Margaret Clagett-Dame
Hector F. Deluca
Lori A. Plum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU2013375208A1 publication Critical patent/AU2013375208A1/en
Application granted granted Critical
Publication of AU2013375208B2 publication Critical patent/AU2013375208B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2013375208A 2013-01-23 2013-12-23 (22E)-2-methylene-22-dehydro-1a,24,25-trihydroxy-19-nor-vitamin D3 analogs Ceased AU2013375208B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361755702P 2013-01-23 2013-01-23
US61/755,702 2013-01-23
US14/084,281 US9416102B2 (en) 2013-01-23 2013-11-19 (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
US14/084,281 2013-11-19
PCT/US2013/077486 WO2014116386A1 (en) 2013-01-23 2013-12-23 (22E)-2-METHYLENE-22-DEHYDRO-1α,24,25-TRIHYDROXY-19-NOR-VITAMIN D3 ANALOGS

Publications (2)

Publication Number Publication Date
AU2013375208A1 AU2013375208A1 (en) 2015-07-23
AU2013375208B2 true AU2013375208B2 (en) 2017-01-12

Family

ID=51208161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013375208A Ceased AU2013375208B2 (en) 2013-01-23 2013-12-23 (22E)-2-methylene-22-dehydro-1a,24,25-trihydroxy-19-nor-vitamin D3 analogs

Country Status (6)

Country Link
US (1) US9416102B2 (enExample)
EP (1) EP2951152B1 (enExample)
JP (1) JP6383365B2 (enExample)
AU (1) AU2013375208B2 (enExample)
CA (1) CA2897527C (enExample)
WO (1) WO2014116386A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524973A (ja) * 2007-04-18 2010-07-22 ジョンズ ホプキンス ユニバーシティ カルシトリオールの低カルシウム血性、高抗増殖性類似体
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
CA3049010A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CN111263749A (zh) * 2017-10-17 2020-06-09 威斯康星校友研究基金会 (22E)-(24R)-2-亚甲基-22-脱氢-1α，24，25-三羟基-19-去甲-维生素D3的结晶方法
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN110272398B (zh) * 2018-03-16 2022-11-29 江苏瑞科医药科技有限公司 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法
CA3094527A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018658A1 (en) * 2003-08-20 2005-03-03 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin d2 compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
AU4645893A (en) * 1992-06-22 1994-01-24 Lunar Corporation Oral 1alpha-hydroxyprevitamin D
GB9214202D0 (en) 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
EP0619306B1 (en) 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substituent at 2-position
ES2130522T3 (es) 1994-12-14 1999-07-01 Duphar Int Res Compuestos de vitamina d y metodo para preparar estos compuestos.
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
WO1998051678A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital CYCLIC ETHER VITAMIN D3 COMPOUNDS, 1α (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND USES THEREOF
GB9721156D0 (en) 1997-10-06 1997-12-03 Leo Pharm Prod Ltd Novel vitamin d analogues
MXPA03001969A (es) 2000-09-08 2003-06-24 Wisconsin Alumni Res Found 1-alfa-hidroxi-2-metilen-19-nor-homopregnacalciferol y sus aplicaciones terapeuticas.
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US8188064B2 (en) * 2003-11-25 2012-05-29 Wisconsin Alumni Research Foundation Vitamin D analogs for obesity prevention and treatment
US8404667B2 (en) 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018658A1 (en) * 2003-08-20 2005-03-03 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin d2 compounds

Also Published As

Publication number Publication date
EP2951152A1 (en) 2015-12-09
US20140206655A1 (en) 2014-07-24
JP6383365B2 (ja) 2018-08-29
CA2897527A1 (en) 2014-07-31
AU2013375208A1 (en) 2015-07-23
CA2897527C (en) 2020-09-22
US9416102B2 (en) 2016-08-16
JP2016509601A (ja) 2016-03-31
EP2951152B1 (en) 2018-08-22
WO2014116386A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
US9416102B2 (en) (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
US7741313B2 (en) 17,20(E)-dehydro vitamin D analogs and their uses
MX2010007266A (es) Análogos de vitamina d, (20s)-23, 23-difluoro-2-metilen-19-nor-bis homopregnacalciferol.
US8445468B2 (en) (20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D3
AU2009268557B2 (en) 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs
JP5629682B2 (ja) ２−メチレン−（１７ｚ）−１７（２０）−デヒドロ−１９，２１−ジノル−ビタミンｄ類似物質
JP2011527700A (ja) ２−メチレン−２０（２１）−デヒドロ−１９−ノル−ビタミンｄ類似物質
JP2011527698A (ja) ２−メチレン−（２０ｅ）−２０（２２）−デヒドロ−１９−ノル−ビタミンｄ類似物質
US20110294764A1 (en) 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3
AU2005309747A1 (en) 2-methylene-18,19-dinor-1alpha-hydroxy-homopregnacalciferol and its uses
JP5931845B2 (ja) ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
US7713953B2 (en) 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs
US20130178449A1 (en) 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs
US8754067B2 (en) 22-haloacetoxy-homopregnacalciferol analogs and their uses
US10479764B2 (en) 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs
US9290447B2 (en) (20R) and (20S)-24-(p-toluenesulfonyloxy)-25,26,27-trinorvitamin D3 analogs and their uses

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ (22E)-2-METHYLENE-22-DEHYDRO-1A,24,25-TRIHYDROXY-19-NOR-VITAMIN D3 ANALOGS

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ DELUCA, HECTOR F.; PLUM, LORI A.; BARYCKI, RAFAL AND CLAGETT-DAME, MARGARET

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN EXTENDED TO 12 MAY 2017

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired